Condition
Paratyphoid Fever
Total Trials
6
Recruiting
1
Active
1
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
4 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 4 (4)
Trial Status
Completed5
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04878549Recruiting
Transcriptomic Responses for the Identification of Pathogens
NCT02192008Not ApplicableCompleted
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
NCT00125008Phase 4Completed
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
NCT00125047Phase 4Completed
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
NCT00131820Phase 4Completed
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
NCT00131833Phase 4Completed
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
Showing all 6 trials